By Michele Maatouk
Date: Tuesday 07 Apr 2026
(Sharecast News) - California-based Gilead Sciences said on Tuesday that it has agreed to buy German clinical stage biotechnology group Tubulis for up to $5bn.
| Currency | US Dollars |
| Share Price | $ 145.23 |
| Change Today | $ -0.36 |
| % Change | -0.25 % |
| 52 Week High | $155.80 |
| 52 Week Low | $110.56 |
| Volume | 1,098,756 |
| Shares Issued | 1,241.00m |
| Market Cap | $180,230m |
| Beta | 0.01 |
| RiskGrade | 120 |
| Strong Buy | 8 |
| Buy | 15 |
| Neutral | 5 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 29 |

| Time | Volume / Share Price |
| 11:24 | 100 @ $145.23 |
| 11:23 | 100 @ $145.23 |
| 11:23 | 100 @ $145.22 |
| 11:23 | 100 @ $145.22 |
| 11:23 | 100 @ $145.22 |
You are here: research